India’s pharmaceutical export machine is not run by a dozen household names alone. Behind the Sun Pharmas and Ciplas, there are 37 mid-size companies — members of the Pharmaceutical Export Promotion Council — that hold active US FDA registrations for 68 manufacturing facilities. They make the active ingredients, press the tablets, and fill the vials that reach patients in countries most people could not find on a map. Nobody writes profiles of them. This page does.
When a pharmacist in Lagos fills a prescription for a blood-pressure medicine, or a hospital in Dhaka stocks its surgical supplies, the name on the packaging is rarely one you would recognise. It belongs to a company in Gujarat, or Andhra Pradesh, or Tamil Nadu — a mid-size manufacturer with a few hundred employees, a handful of buildings registered with the US Food and Drug Administration, and a quiet competence that has earned it a place in global pharmaceutical supply chains without ever earning a headline.
India’s Pharmaceutical Export Promotion Council (Pharmexcil) has 5,158 members. Of those, 37 meet a specific threshold: they are not members of the Indian Pharmaceutical Alliance (the industry’s big-company group) and they are not subsidiaries of multinational OPPI members, but they have earned and maintained US FDA registration for at least one manufacturing facility. That registration is not a formality. It means each facility is listed in the FDA’s public register, subject to FDA oversight and periodic inspection, and required to comply with US current Good Manufacturing Practice (cGMP) regulations — the same standards that apply to any facility supplying the American market.
Together, these 37 companies operate 68 FDA-registered facilities across 13 Indian states. Twenty-three manufacture active pharmaceutical ingredients — the raw molecules that become the medicines. Thirteen produce finished dosage forms. One holds sterile manufacturing capability, the most demanding FDA classification. Seventeen hold DGFT Star Export House status — the Indian government’s recognition of sustained export performance, awarded on a scale from One Star to Five Star. Most are privately held. Most have never issued a press release in English. And most are essential to the supply of affordable medicine in countries that cannot afford to source from Europe or the United States.
Gujarat leads with ten facilities across nine companies — the state’s pharmaceutical corridor between Ahmedabad and Vadodara has been attracting API manufacturers for decades, drawn by chemical industry infrastructure and port access. Andhra Pradesh and Telangana together account for another ten, clustered around Hyderabad’s bulk-drug district. Tamil Nadu, Maharashtra, Himachal Pradesh, and Uttarakhand round out the manufacturing map, each bringing distinct advantages: port proximity, tax incentives, or cooler climates for temperature-sensitive production.
The distinction matters. An API manufacturer synthesises the active molecule itself — the chemical compound that treats the disease. A finished-dose manufacturer turns that molecule into the pill, capsule, injection, or ointment that a patient actually uses. The two require different expertise, different equipment, and different FDA registrations.
Among these 37 companies, 23 hold FDA registration for API manufacturing. Companies like Malladi Drugs & Pharmaceuticals, operating three FDA-registered facilities across Andhra Pradesh and Tamil Nadu, specialise entirely in the active ingredients that other manufacturers buy and formulate. Acharya Chemicals in Gujarat, SVR Drugs and Intermediates, and Macsen Drugs do the same. They are the upstream of the upstream — the suppliers to the suppliers.
The finished-dose manufacturers are a different breed. Fourrts Laboratories in Chennai, Novamed in Haryana, Oxalis Labs and Pinnacle Life Sciences in Himachal Pradesh — these companies take raw APIs and turn them into the tablets and capsules that end up in pharmacies. Their FDA registrations cover not just manufacturing but analysis, labelling, and packaging — the full chain from bulk compound to boxed product.
One company, Galentic Pharma in Gujarat, holds the rarest credential of all: FDA-registered sterile manufacturing. The ability to manufacture sterile ophthalmic and dermatological products under aseptic conditions places it in a category that most companies in any country never reach.
India’s Directorate General of Foreign Trade awards Star Export House status to companies that have demonstrated sustained export performance over multiple years. The designation runs from One Star (the entry threshold) to Five Star (reserved for the largest exporters in the country). Among these 37 hidden champions, 17 hold Star Export House status — independent government recognition that these are not occasional exporters but companies with a track record of consistent international trade.
Five companies — NGL Fine-Chem, Milan Laboratories, Fourrts, Haleos Labs, and Swati Menthol — hold Three Star status, the highest tier among these hidden champions. Six are Two Star, and six more are One Star. These are not self-reported claims; they are published in the DGFT’s official gazette after verification of export turnover data.
Every company listed below is a Pharmexcil member with at least one active US FDA-registered manufacturing facility. They are not IPA members, not OPPI-affiliated multinationals, and not the well-known contract development organisations. They are the companies that make India’s $31 billion pharmaceutical export number possible.
Sources: US FDA facility registration data (active registrations). Pharmaceutical Export Promotion Council of India (Pharmexcil) member directory (5,158 members). Directorate General of Foreign Trade (DGFT) Star Export House status holders. Indian Pharmaceutical Alliance (IPA) member list (ipa-india.org). Organisation of Pharmaceutical Producers of India (OPPI) member list (indiaoppi.com). Individual company details from company websites where indicated. Company classification: “hidden champion” = Pharmexcil member with active US FDA registration, excluding IPA members, OPPI members, and established contract development organisations.